Should I Buy IH? IH 2026 Analysis

Should You Buy iHuman Inc (IH) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.810

1 Day change

52 Week Range

3.600

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: trend is still bearish (SMA_200 > SMA_20 > SMA_5) and Intellectia has no buy signals today.
Pre-market price (~1.80) is below the pivot (1.814) and sitting near support (1.79/1.774), which makes it more of a “wait/avoid chasing” setup than an immediate buy.
With no fresh news catalysts, neutral hedge fund/insider activity, and YoY revenue/net income declines in the latest reported quarter, the risk/reward for an impatient entry is not attractive today.

Technical Analysis

Trend: Bearish structure (SMA_200 > SMA_20 > SMA_5) indicates the broader downtrend is still intact.
Momentum (MACD): MACD histogram is above 0 (0.0154) but positively contracting → bullish momentum is fading rather than strengthening.
RSI (short-term): RSI_6 at 23.78 suggests oversold conditions (potential for a bounce), but oversold alone is not a reliable buy trigger without confirmation.
Key levels:
- Pivot: 1.814 (price ~1.80 is below it)
- Support: 1.79 (S1) then 1.774 (S2)
- Resistance: 1.839 (R1) then 1.855 (R2)
Pattern-based forward odds (given): only modest edge (about +0.41% next week, +2.09% next month with ~50% probability) → not strong enough to override the bearish trend.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Positive Catalysts

- Oversold RSI_6 (~23.8) increases the odds of a short-term technical bounce if support holds.
- MACD histogram remains slightly positive, implying downside momentum is not aggressively accelerating at this moment.
- No negative news flow in the last week (absence of fresh headline risk).

Neutral/Negative Catalysts

- Primary trend is bearish (moving averages stacked negatively), which often caps bounce attempts.
- MACD positive but contracting signals weakening upward momentum.
- Latest reported quarter shows YoY revenue decline (-14.05%) and YoY net income decline (-14.15%), reducing fundamental support.
- No identified near-term event catalyst (news is quiet), and hedge fund/insider activity is neutral (no signal of strong accumulation).
- Political/congress activity: no data showing influential buying support (no recent congress trading data available).

Financial Performance

Latest quarter: 2025/Q3
Revenue: 205,764,000, -14.05% YoY (top-line contraction).
Net Income: 21,585,000, -14.15% YoY (profit also down YoY).
EPS: 0.40, +344.44% YoY (disconnect vs. revenue/net income suggests possible share-count changes or non-operating effects; not clearly indicative of accelerating core growth).
Gross Margin: 68.35%, -0.15% YoY (slightly weaker margins).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there’s no visible recent Wall Street upgrade/downgrade trend to support an immediate buy.
Practical read-through (pros vs cons view):
- Pros: potential value/mean-reversion appeal after selloff; EPS print looks strong on the surface.
- Cons: declining revenue and net income YoY, and the chart remains in a clear bearish structure—typical reasons analysts would hesitate to turn broadly bullish without evidence of re-acceleration.

Analyst Rating

Wall Street analysts forecast IH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IH is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 1.810

Low

Averages

High